Search Results - "Herukka, S.‐K."

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings by SEPPÄLÄ, T. T, NERG, O, JÄÄSKELÄINEN, J. E, RINNE, J, SOININEN, H, LEINONEN, V, HERUKKA, S.-K, KOIVISTO, A. M, RUMMUKAINEN, J, PULI, L, ZETTERBERG, H, PYYKKÖ, O. T, HELISALMI, S, ALAFUZOFF, I, HILTUNEN, M

“…To assess the relationship between Alzheimer disease (AD)-related pathologic changes in frontal cortical brain biopsy and AD biomarkers in ventricular vs…”
Get full text

Age and diagnostic performance of Alzheimer disease CSF biomarkers by MATTSSON, N, ROSEN, E, RICH, K, KAISER, E, VERBEEK, M. M, RIKKERT, M. Olde, TSOLAKI, M, MULUGETA, E, AARSLAND, D, VISSER, P. J, SCHRÖDER, J, MARCUSSON, J, HANSSON, O, DE LEON, M, HAMPEL, H, SCHELTENS, P, WALLIN, A, ERIKSDOTTER-JÖNHAGEN, M, MINTHON, L, WINBLAD, B, BLENNOW, K, ZETTERBERG, H, ANDREASEN, N, PARNETTI, L, JONSSON, M, HERUKKA, S.-K, DER FLIER, W. M. Van, BLANKENSTEIN, M. A, EWERS, M

“…Core CSF changes in Alzheimer disease (AD) are decreased amyloid β(1-42), increased total tau, and increased phospho-tau, probably indicating amyloid plaque…”
Get full text

Protein tyrosine phosphatase receptor type Q in cerebrospinal fluid reflects ependymal cell dysfunction and is a potential biomarker for adult chronic hydrocephalus by Nakajima, M., Rauramaa, T., Mäkinen, P. M., Hiltunen, M., Herukka, S.‐K., Kokki, M., Musialowicz, T., Jyrkkänen, H.‐K., Danner, N., Junkkari, A., Koivisto, A. M., Jääskeläinen, J. E., Miyajima, M., Ogino, I., Furuta, A., Akiba, C., Kawamura, K., Kamohara, C., Sugano, H., Tange, Y., Karagiozov, K., Leinonen, V., Arai, H.

“…Background and purpose Protein tyrosine phosphatase receptor type Q (PTPRQ) was extracted from the cerebrospinal fluid (CSF) of patients with probable…”
Get full text

Metabolome in progression to Alzheimer's disease by Orešič, M, Hyötyläinen, T, Herukka, S-K, Sysi-Aho, M, Mattila, I, Seppänan-Laakso, T, Julkunen, V, Gopalacharyulu, P V, Hallikainen, M, Koikkalainen, J, Kivipelto, M, Helisalmi, S, Lötjönen, J, Soininen, H

“…Mild cognitive impairment (MCI) is considered as a transition phase between normal aging and Alzheimer's disease (AD). MCI confers an increased risk of…”
Get full text

PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment by Koivunen, J, Pirttilä, T, Kemppainen, N, Aalto, S, Herukka, S-K, Jauhianen, A M, Hänninen, T, Hallikainen, M, Någren, K, Rinne, J O, Soininen, H

“…In mild cognitive impairment (MCI), Alzheimer's disease (AD)-type cerebrospinal fluid (CSF) biomarker profiles predict rapid progression and conversion to AD…”
Get more information

Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study by Seppälä, T T, Herukka, S-K, Hänninen, T, Tervo, S, Hallikainen, M, Soininen, H, Pirttilä, T

“…BackgroundSingle measurements of plasma Aβ are not useful in the diagnostics of Alzheimer's disease (AD). However, changes in plasma Aβ levels during repeated…”
Get full text

Genetic study evaluating LDLR polymorphisms and Alzheimer's disease by Lämsä, R, Helisalmi, S, Herukka, S.-K, Tapiola, T, Pirttilä, T, Vepsäläinen, S, Hiltunen, M, Soininen, H

“…Abstract We genotyped SNPs rs11668477, rs12983082, rs11669576, rs2738444, rs5925 and rs1433099 in 405 Finnish AD cases and 463 controls and conducted a single…”
Get full text

The association study between DHCR24 polymorphisms and Alzheimer's disease by Lämsä, R., Helisalmi, S., Hiltunen, M., Herukka, S.-K., Tapiola, T., Pirttilä, T., Vepsäläinen, S., Soininen, H.

“…DHCR24 gene in chromosome 1 encodes seladin 1, a cholesterol synthesizing enzyme. Seladin 1 protects neurons from Aβ42 mediated toxicity and participates in…”
Get full text

Study on the association between SOAT1 polymorphisms, Alzheimer's disease risk and the level of CSF biomarkers by Lamsa, R, Helisalmi, S, Herukka, S-K, Tapiola, T, Pirttila, T, Vepsalainen, S, Hiltunen, M, Soininen, H

“…In Alzheimer's disease (AD) the beta-amyloid precursor protein is excessively cleaved into Abeta(42), causing the abundant amyloid plaque loads in affected…”
Get more information

Plasma A 42 and A 40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study by Seppala, T. T., Herukka, S.-K., Hanninen, T., Tervo, S., Hallikainen, M., Soininen, H., Pirttila, T.

“…Background Single measurements of plasma Aβ are not useful in the diagnostics of Alzheimer's disease (AD). However, changes in plasma Aβ levels during repeated…”
Get full text

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment by Mattsson, Niklas, Zetterberg, Henrik, Hansson, Oskar, Andreasen, Niels, Parnetti, Lucilla, Jonsson, Michael, Herukka, Sanna-Kaisa, van der Flier, Wiesje M, Blankenstein, Marinus A, Ewers, Michael, Rich, Kenneth, Kaiser, Elmar, Verbeek, Marcel, Tsolaki, Magda, Mulugeta, Ezra, Rosén, Erik, Aarsland, Dag, Visser, Pieter Jelle, Schröder, Johannes, Marcusson, Jan, de Leon, Mony, Hampel, Harald, Scheltens, Philip, Pirttilä, Tuula, Wallin, Anders, Jönhagen, Maria Eriksdotter, Minthon, Lennart, Winblad, Bengt, Blennow, Kaj

“…CONTEXT Small single-center studies have shown that cerebrospinal fluid (CSF) biomarkers may be useful to identify incipient Alzheimer disease (AD) in patients…”
Get full text

Circulating neurofilament is linked with morbid obesity, renal function, and brain density by Rebelos, Eleni, Rissanen, Eero, Bucci, Marco, Jääskeläinen, Olli, Honka, Miikka-Juhani, Nummenmaa, Lauri, Moriconi, Diego, Laurila, Sanna, Salminen, Paulina, Herukka, Sanna-Kaisa, Singhal, Tarun, Nuutila, Pirjo

“…Neurofilament light chain (NfL) is a novel biomarker reflecting neuroaxonal damage and associates with brain atrophy, and glial fibrillary acidic protein…”
Get full text

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia by Simonsen, Anja Hviid, Herukka, Sanna-Kaisa, Andreasen, Niels, Baldeiras, Ines, Bjerke, Maria, Blennow, Kaj, Engelborghs, Sebastiaan, Frisoni, Giovanni B, Gabryelewicz, Tomasz, Galluzzi, Samantha, Handels, Ron, Kramberger, Milica G, Kulczyńska, Agnieszka, Molinuevo, Jose Luis, Mroczko, Barbara, Nordberg, Agneta, Oliveira, Catarina Resende, Otto, Markus, Rinne, Juha O, Rot, Uroš, Saka, Esen, Soininen, Hilkka, Struyfs, Hanne, Suardi, Silvia, Visser, Pieter Jelle, Winblad, Bengt, Zetterberg, Henrik, Waldemar, Gunhild

“…Abstract This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical…”
Get full text

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment by Herukka, Sanna-Kaisa, Simonsen, Anja Hviid, Andreasen, Niels, Baldeiras, Ines, Bjerke, Maria, Blennow, Kaj, Engelborghs, Sebastiaan, Frisoni, Giovanni B., Gabryelewicz, Tomasz, Galluzzi, Samantha, Handels, Ron, Kramberger, Milica G., Kulczyńska, Agnieszka, Molinuevo, Jose Luis, Mroczko, Barbara, Nordberg, Agneta, Oliveira, Catarina Resende, Otto, Markus, Rinne, Juha O., Rot, Uroš, Saka, Esen, Soininen, Hilkka, Struyfs, Hanne, Suardi, Silvia, Visser, Pieter Jelle, Winblad, Bengt, Zetterberg, Henrik, Waldemar, Gunhild

“…This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of…”
Get full text

CSF biomarkers for Alzheimer's pathology and the effect size of APOE ε4 by ANDREASSON, U, LAUTNER, R, MINTHON, L, HARDY, J, BLENNOW, K, ZETTERBERG, H, SCHOTT, J. M, MATTSSON, N, HANSSON, O, HERUKKA, S.-K, HELISALMI, S, EWERS, M, HAMPEL, H, WALLIN, A

Get full text

Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study by Zwan, Marissa D, Rinne, Juha O, Hasselbalch, Steen G, Nordberg, Agneta, Lleó, Alberto, Herukka, Sanna-Kaisa, Soininen, Hilkka, Law, Ian, Bahl, Justyna M C, Carter, Stephen F, Fortea, Juan, Blesa, Rafael, Teunissen, Charlotte E, Bouwman, Femke H, van Berckel, Bart N M, Visser, Pieter J

“…To define CSF β-amyloid 1-42 (Aβ42) cutpoints to detect cortical amyloid deposition as assessed by 11C-Pittsburgh compound B ([11C]PiB)-PET and to compare…”
Get full text

Blood plasma IgG Fc glycans are significantly altered in Alzheimer's disease and progressive mild cognitive impairment by Lundström, Susanna L, Yang, Hongqian, Lyutvinskiy, Yaroslav, Rutishauser, Dorothea, Herukka, Sanna-Kaisa, Soininen, Hilkka, Zubarev, Roman A

“…Blood-based anti-amyloid-β (Aβ) immunoglobulins (IgGs) and peripheral inflammation are factors correlating with development of Alzheimer's disease (AD). IgG…”
Get more information

Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression by Yang, Hongqian, Lyutvinskiy, Yaroslav, Herukka, Sanna-Kaisa, Soininen, Hilkka, Rutishauser, Dorothea, Zubarev, Roman A

“…Patients with mild cognitive impairment (MCI) have varying risks of progression to Alzheimer's disease (AD). To test the utility of the relative abundances of…”
Get more information

Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study by Reijs, Babette L R, Vos, Stephanie J B, Soininen, Hilkka, Lötjonen, Jyrki, Koikkalainen, Juha, Pikkarainen, Maria, Hall, Anette, Vanninen, Ritva, Liu, Yawu, Herukka, Sanna-Kaisa, Freund-Levi, Yvonne, Frisoni, Giovanni B, Frölich, Lutz, Nobili, Flavio, Rikkert, Marcel Olde, Spiru, Luiza, Tsolaki, Magda, Wallin, Åsa K, Scheltens, Philip, Verhey, Frans, Visser, Pieter Jelle

“…Lifestyle factors have been associated with the risk of dementia, but the association with Alzheimer's disease (AD) remains unclear. To examine the association…”
Get more information

Structural MRI in frontotemporal dementia: comparisons between hippocampal volumetry, tensor-based morphometry and voxel-based morphometry by Muñoz-Ruiz, Miguel Ángel, Hartikainen, Päivi, Koikkalainen, Juha, Wolz, Robin, Julkunen, Valtteri, Niskanen, Eini, Herukka, Sanna-Kaisa, Kivipelto, Miia, Vanninen, Ritva, Rueckert, Daniel, Liu, Yawu, Lötjönen, Jyrki, Soininen, Hilkka

“…MRI is an important clinical tool for diagnosing dementia-like diseases such as Frontemporal Dementia (FTD). However there is a need to develop more accurate…”
Get full text